Interim results of a phase II multicenter study with the oral histone deacetylase inhibitor abexinostat in patients with relapsed/refractory follicular lymphoma.

Gui, L; Cheng, Y; Wang, H; Cao, J; Li, Z; Zhang, L; Gao, Y; Li, Y; Xu, W; Li, X; Ke, X; Jing, H; Zhang, Q; Xi, Y; Liu, T; Wang, Z; Gao, Y; Pan, Q; Zou, L; Shi, Y

JOURNAL OF CLINICAL ONCOLOGY, 2022; 40 (16):

Abstract

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索